^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    apitolisib (GDC-0980)

    i
    Company:
    Roche
    Drug class:
    mTOR inhibitor, PI3K inhibitor
    Related drugs:
    Apply
    Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy (NCT01485861)
    Phase 1/2
    Genentech, Inc.
    Completed
    Last update posted :
    09/14/2023
    Initiation :
    01/11/2012
    Primary completion :
    09/01/2015
    Completion :
    08/31/2022
    PTEN
    |
    PTEN loss
    |
    docetaxel • abiraterone acetate • ipatasertib (RG7440) • prednisone • apitolisib (GDC-0980)
    Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy (NCT01437566)
    Phase 2
    Genentech, Inc.
    Completed
    Last update posted :
    11/02/2016
    Initiation :
    10/01/2011
    Primary completion :
    04/01/2016
    Completion :
    04/01/2016
    HER-2 • ER • PIK3CA
    |
    ER positive • HER-2 negative • PIK3CA mutation
    |
    fulvestrant • pictilisib (GDC-0941) • apitolisib (GDC-0980)
    Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer (NCT01254526)
    Phase 1
    Genentech, Inc.
    Completed
    Last update posted :
    11/02/2016
    Initiation :
    12/01/2010
    Primary completion :
    07/01/2012
    Completion :
    04/01/2013
    HER-2
    |
    HER-2 overexpression
    |
    Avastin (bevacizumab) • paclitaxel • apitolisib (GDC-0980)